Hand-Foot Syndrome
Conditions
Keywords
acupuncture, laser acupuncture, chemotherapy, target therapy, hand-foot syndrome
Brief summary
Chemotherapy or target therapy-induced hand-foot syndrome in cancer patients affects the quality of life. At present, there is no better treatment for this side effect of chemotherapy or target therapy. In severe cases, it is necessary to reduce the dose of chemotherapy or target therapy, which may affect the progress and effect of chemotherapy. In recent years, acupuncture has been widely used for many side effects of chemotherapy, such as numbness of hands and feet, gastrointestinal discomfort, and dizziness. There have been many studies have proved to be effective, but quite few studies explored the acupuncture treatment improves the hand-foot syndrome caused by chemotherapy or target therapy in cancer patients. Therefore, the investigators expect to evaluate the efficacy of acupuncture, and applying acupuncture or laser acupuncture to improve hand-foot syndrome caused by chemotherapy or target therapy in cancer patients in the future.
Detailed description
The investigators design a single-center, sham-controlled, assessor- and subject- blind, randomized clinical trial. 60 subjects will be equally and randomly divided into an acupuncture group, laser acupuncture, and sham-laser acupuncture groups in the 6-week trial. Each subject receives acupuncture, laser acupuncture, or sham-laser acupuncture three times a week for three consecutive weeks depending on their group, with a total of 9 times interventions. Outcome measures include Common adverse events evaluation standard version 5.0 (CTCAE) and Visual Analogue Scale (VAS), Dermatology Life Quality Index (DLQI) and assessment of cancer patients' quality of life questionnaire (EORTC QLQ-C30). ANSWatch and Thermal Image Camera are also used to assess those subjects. Those outcome measures will be conducted at baseline, the 3rd and the 6th week after the interventions.
Interventions
DEVICEacupuncture
acupuncture
DEVICElaser acupuncture
laser acupuncture
DEVICESham-laser acupuncture
Sham-laser acupuncture
Sponsors
China Medical University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Cancer patients receiving chemotherapy or targeted therapy 2. Age over 20 years old 3. Western medicine diagnoses hand-foot syndrome 4. Sign the consent form
Exclusion criteria
1. Pregnant or planning to become pregnant 2. Serious arrhythmia (or cardiac pacemaker installed) 3. Epilepsy 4. Severe organ failure, such as heart and lung failure, liver and kidney failure 5. Psychiatric history, unable to cooperate with acupuncture and assessors 6. Those who received traditional Chinese medicine treatment for hand-foot skin reaction
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The change of temperature of limbs before and after treatment | Change from Baseline temperature at 3 weeks | testing temperature assessed by Thermal Imaging Analysis |
| The change of Common Terminology Criteria for Adverse Events (CTCAE) version 5. 0 | Change from Baseline severity of hand-foot syndrome at 3 weeks | Evaluate skin symptoms assessed by Common Terminology Criteria for Adverse Events version 5. 0 (total three grade. Grade 1 is minimal skin changes, and grade 3 is severe skin changes) |
| The change of scores of Visual analogue scale (VAS) | Change from Baseline severity of pain at 3 weeks | pain evaluation assessed by Visual analogue scale, score from 0 (no pain) to 10 (unbearable pain) |
| The change of Dermatology Life Quality Index (questionnaire) | Change from Baseline quality of life at 3 weeks | evaluate quality of life assessed by Dermatology Life Quality Index |
| The change of EORTC QLQ-C30 (questionnaire) | Change from Baseline quality of life at 3 weeks | evaluate quality of life assessed by EORTC QLQ-C30 |
| The change of LF/HF before and after treatment | Change from Baseline LF/HF at 3 weeks | testing LF/HF assessed by ANSWatch wrist monitor |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The change of Common Terminology Criteria for Adverse Events (CTCAE) version 5. 0 | Change from Baseline severity of hand-foot syndrome at 6 weeks | Evaluate skin symptoms assessed by Common Terminology Criteria for Adverse Events version 5. 0 (total three grade. Grade 1 is minimal skin changes, and grade 3 is severe skin changes) |
| The change of scores of Visual analogue scale (VAS) | Change from Baseline severity of pain at 6 weeks | pain evaluation assessed by Visual analogue scale, score from 0 (no pain) to 10 (unbearable pain) |
| The change of Dermatology Life Quality Index (questionnaire) | Change from Baseline quality of life at 6 weeks | evaluate quality of life assessed by Dermatology Life Quality Index |
| The change of EORTC QLQ-C30 (questionnaire) | Change from Baseline quality of life at 6 weeks | evaluate quality of life assessed by EORTC QLQ-C30 |
| The change of LF/HF before and after treatment | Change from Baseline LF/HF at 6 weeks | testing LF/HF assessed by ANSWatch wrist monitorng LF/HF |
| The change of temperature of limbs before and after treatment | Change from Baseline temperature at 6 weeks | testing temperature assessed by Thermal Imaging Analysis |
Outcome results
None listed